Purpose of Review This review summarizes recent data about antibodies after cardiac transplantation, what testing modalities are available and how frequently to employ them, and when treatment is necessary. Recent Findings Technologies available for antibody detection have progressed over the past couple decades. New and preformed antibodies are associated with worse outcomes in transplant recipients. Summary The frequency of screening for post-transplant antibodies and for antibody-mediated rejection (AMR) should be based on risk stratification. The presence of antibodies alone post transplant does not constitute a diagnosis of AMR. Treatment of post-transplant antibodies and AMR should be made in conjunction with consideration of AMR grade and graft dysfunction. Future directions will involve improved detection methods and further understanding of non-HLA antibodies and de novo antibodies in the posttransplant population. Additionally, aggressive efforts are currently underway to provide more therapeutic options.
Introduction
In the past couple decades, antibody-mediated rejection (AMR) has become recognized as the process that underlies hyperacute, early, and delayed rejection following cardiac allograft transplantation. It is associated with decreased survival and poor prognosis. However, management of antibodies after heart transplantation without clinical AMR is challenging and controversial. Specifically, there are prognostic differences whether the antibodies are de novo or persistent in a patient who was sensitized pre transplant. In addition, technologies available for antibody detection have progressed over the past couple decades to provide better stratification for immunological risk. Whether this risk translates to poor outcomes such as AMR or biopsy-negative graft dysfunction is difficult to predict.
Accordingly, transplant physicians are faced with complex clinical scenarios with increasing frequency. Much of the objective evidence to guide management is limited to clinical data based on single-center experiences and consensus. This review summarizes recent data to address which antibodies are relevant to cardiac transplantation and AMR, what testing modalities are available, how frequently to employ them, and when treatment is necessary.
antibodies (Table 1) . This is reflective of the level of understanding of their respective antigens.
Human leukocyte antigens derive from the major histocompatibility complex (MHC) located on chromosome 6 and consist of self-recognizing cell surface molecules that allow the immune system to distinguish host from pathogen. The major classes of HLA relevant to solid organ transplant are I and II. Class I molecules include HLA-A, B, and C. Class II molecules include HLA DR, DP, and DQ. Antibodies that react to these antigens form antigen-antibody complexes along the allograft endothelial layer and cause activation of the complement cascade. This results in an inflammatory response characterized by increased vascular permeability, macrophage infiltration, microvascular thrombosis, and subsequent allograft dysfunction [2] . While all nucleated cells express HLA class I molecules, HLA class II molecules are limited to antigen-presenting cells such as B cells.
As part of the pre-transplant evaluation, potential transplant recipients are screened for anti-HLA antibodies to assess the patient's immunologic risk for antibody-mediated rejection (AMR). Development of antibodies pre transplant, termed allosensitization, results from antigenic exposure to foreign antigens. HLA antibodies often develop as a result of pregnancy, blood transfusion, or previous transplantation. Platelet transfusions have more of an antigenic impact than red blood cell transfusions, particularly with leukocyte-filtered products [3] . Additionally relevant risk factors for allosensitization include specific HLA phenotypes (namely, HLA-DRB1*01 and HLA-DRB1*03), left ventricular assist device (LVAD) implantation, and viral infections, including hepatitis C and cytomegalovirus (CMV) [4, 5] . The latter is particularly relevant for the development of the non-HLA antibodies, namely, antiendothelial cell antibodies, which have been shown to increase following CMV DNA detection [6] . Regarding LVAD implantation, studies previously demonstrated that the HeartMate XVE device resulted in greater antibody production than the HeartMate II LVAD [7] , although more recent reports suggest less difference by LVAD type (pulsatile versus continuous) with mixed results on clinical post-transplant outcomes [8] [9] [10] [11] [12] .
When a transplant recipient has an antibody (old or new) against the donor's HLA antigen, this anti-HLA antibody is termed a donor-specific antibody (DSA). Because DSAs, particularly de novo antibodies, are associated with poor outcomes after heart transplant, it is important to understand differences in the development and detection of pre-existing versus de novo antibodies [13] [14] [15] [16] . There are two mechanisms that result in "new" expression of antibodies after transplant. The first involves cell memory in the pre-sensitized patient, whereby re-exposure to a previously recognized antigen results in a recall response with rapid antibody production early in the post-transplant period. HLA class I antibodies are commonly the culprit DSA. The second is more delayed whereby the heart transplant recipient develops new DSA; these are frequently class II antibodies. In order to screen for de novo antibodies, there is current recommendation for posttransplant testing for DSA within the first 90 days after transplantation (earlier and more frequently if the patient was sensitized), or when AMR is suspected [17••] . Of note, antibodies against HLA class II antigens, particularly HLA-DQ antigens, are more likely to be persistent as well as to be associated with worse long-term outcomes, such as with cardiac allograft vasculopathy (CAV) and chronic rejection [14, [18] [19] [20] .
Non-HLA antibodies should be considered as a cause of AMR if there is suspicion without evidence of HLA antibodies. The mechanism of non-HLA antibody-mediated cell 
Antibody-Mediated Rejection
In contrast to lymphocyte-mediated cellular rejection, AMR acts through antibodies to attack the donor graft. . Accordingly, the most current definition requires both histologic and immunopathologic evidence to support a diagnosis. In an effort to stratify the severity of disease with consideration of histologic and immunopathologic findings, the ISHLT consensus group defined four different categories of pathologic AMR (pAMR) in order to represent this spectrum [28••] . Thus, pAMR 0 suggests negativity (by both histopathology and immunopathology), pAMR 1 suggests suspicion (H+: histological findings present, immunopathologic findings negative; or I+: immunopathologic findings present, histological findings negative), pAMR 2 suggests pathologic disease (both histological and immunopathologic findings present), and pAMR 3 suggests severe pathologic disease (immunopathology with severe histopathology).
Immunopathology is vital to the identification of AMR and requires special preparation of frozen biopsy samples for immunofluorescence. Immunopathologic requirements include evidence of immunoglobulin (IgG, IgM, or IgA) and complement deposition by immunofluorescence, staining of macrophages and/or complement by paraffin immunohistochemistry with immunoperoxidase staining, or appearance of fibrin in vessels [26] . Histologic requirements for pAMR include evidence of capillary endothelial changes and macrophage infiltration. Severe histopathologic features include interstitial hemorrhage, capillary fragmentation, mixed inflammatory infiltrates, endothelial cell pyknosis and/or karyorrhexis, and marked edema. To diagnose pAMR, optimal staining by immunofluorescence should include both C3d and C4d, and immunoperoxidase staining of C4d is sufficient for immunohistochemistry.
While the presence of DSA is relevant for prognostication of outcomes as well as in supporting suspicion of AMR, it is not required for the diagnosis of AMR. In other words, the presence of DSA alone post transplant does not constitute a diagnosis of pathologic or clinical AMR. Moreover, differentiating subclinical AMR (diagnosis by pathology only) from clinical AMR depends on the clinical scenario. The diagnosis and management of clinical AMR has been variable and recently summarized by a consensus conference in 2010 [27] , a scientific statement from the American Heart Association in 2015 [17••] , and a consensus document for improving diagnostics for AMR from the XIIIth Banff Conference in 2015 [30••] . In addition to routine immunopathologic screening for AMR in the first year post transplant, recommendations have been made to also screen for DSA.
Testing Modalities for Antibody Monitoring After Cardiac Transplantation
Screening for anti-HLA antibodies and post-transplant testing for DSAs includes cell-based assays (complement-dependent cytotoxicity [CDC] and flow cytometry) and solid-phase immunoassays (enzyme-linked immunosorbent assays [ELISA] and polystyrene bead-based array assays). HLA antibody detection for pre-transplant screening was first managed with the cell-based CDC assays, which were relatively non-specific and insensitive, followed by flow cytometry which was more sensitive. Subsequently, development of solid-phase immunoassays (SPI) resulted in even greater sensitivity in the detection of specific HLA antibodies, especially those that are donor-specific, for both pre-and post-transplant monitoring. Adjunctive techniques and assays should be considered to further characterize the potential clinical significance of detected antibodies.
Solid-phase immunoassays are the current technique for post-transplant antibody monitoring. Developed in the mid1990s, this technique involves attachment of purified or recombinant HLA antigens to a carrier, such as an ELISA plate or plastic bead(s). A broad array of antigens can be attached to the carrier thereby enhancing the sensitivity of this assay. While ELISA provides a semi-quantitative assessment of antibody binding, this technique is no longer used by HLA laboratories because of the superiority of bead-based array assays for SPI, particularly those performed on the Luminex instrument (typically referred to as the Luminex assay) [31] [32] [33] .
To briefly describe the Luminex bead-based assay, polystyrene beads are impregnated with different ratios of two fluorescent dyes (classifier signals) to yield up to 100 different bead populations. The antiglobulin reagent is labeled with a third fluorescent dye (the reporter signal) so that the fluorescence signature of each bead can be subsequently interrogated with a dual-laser instrument, to identify the bead population by one laser, and to simultaneously assess HLA-specific antibody binding via the reporter fluorescence. Antibody binding to the beads must be IgG antibodies since the fluorochromeconjugated secondary (reporter) antibody to detect the binding is anti-human IgG and can be designed to have immunoglobulin-type or subclass specificity. Autoantibodies do not bind HLA-coated beads in solid-phase assays, allowing the differentiation of HLA antibodies with clinical relevance. The three types of antigen panels used for bead-based assays include pooled antigen panels, phenotype panels, and singleantigen beads (SAB).
SAB arrays are the most sensitive and specific, whereby each bead population is coated with a molecule representing a single cloned allelic HLA class I or II antigen to determine the specific HLA antibodies in HLA antibody-positive serum [34••]. Thus, SAB arrays provide the highest degree of HLA antibody resolution with a comprehensive array of common and many rare HLA alleles for all 11 HLA loci (HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPBA1, and DPB1).
HLA antibodies can be semi-quantified into broad categories (e.g., low or high) according to the mean fluorescence intensity (MFI) for the Luminex-based assays and the median channel of fluorescence (MCF) for flow cytometry crossmatch (FCXM). While antibody titer is the true quantitative measurement of antibody level, high titer and high MFI value are not synonymous. Most HLA labs use a MFI cutoff of between 1000 and 5000 for reporting as potentially clinically significant. But the MFI level may not correlate with risk of AMR for a variety of reasons [35•]. These include interference from cryptic epitopes with HLA antibody as well as SAB inhibition from intrinsic and extrinsic factors [30••] .
To better understand the significance of detected HLA antibodies, modifications have been made to SPI in order to distinguish complement-binding from non-complementbinding antibodies, including the C4d, C3d, and C1q assays [36, 37] . Among these, the C1q assay is considered the most clinically relevant because it is highly sensitive and also detects IgM complement-fixing antibodies [38] . Thus, it is prognostically important for identifying patients at high risk for poor outcomes and is available in many HLA laboratories [39] . Nevertheless, the complement-binding assay in general
has not yet been accepted as standard practice by all HLA laboratories because of its cost, and its dependency and correlation with antibody titer; thus, additional studies are required to establish its clinical role as a routine test [39] .
Risk Stratification for Monitoring and Treatment
According to a 2013 Transplantation Society Consensus Guideline addressing antibody management after solid organ transplantation, frequency of monitoring should be based on risk stratification for developing AMR [34••]. Low-risk patients are those that are non-sensitized with a first transplant; intermediate-risk are those with prior HLA antibodies who are currently negative; high-risk are those with positive DSA but negative XM; and very high-risk are those who have been desensitized. Frequency of screening is fairly minimal in the low-risk patient (e.g., at least once between the 3rd and 12th month post transplant, with changes in clinical status), and more frequently with increasing risk for AMR, as outlined in Fig. 1 .
In addition to those at intermediate risk for AMR with prior HLA antibodies, it has been suggested to also include patients treated with mechanical circulatory support such as LVADs, homografts for congenital heart defects, multiple transfusion, prior transplantation, and numerous prior childbirths in the intermediate category [12, 40, 41 •]. These individuals should be monitored for DSA early post transplant and, if present, frequently enough to determine persistence and stability with adjunctive testing (e.g., complement binding, antibody strength/titer, or Ig subclass) for further risk stratification if clinically indicated [13, 14, 19] .
High-risk individuals should also include those who develop de novo DSA in addition to those who have positive DSA but negative XM. DSA should be screened relatively frequently with adjunctive testing as needed. Increased surveillance for rejection by biopsy and assessment of adequate immunosuppression should be considered, especially in the setting of isolated high-risk DSA (e.g., high levels or titers, complement-binding, class II antibodies, persistent antibodies). While very high-risk individuals should also undergo frequent monitoring, the difference in their management is a lower threshold for treatment (Fig. 2) .
Management of Antibodies
The management of antibodies before or after transplantation depends on the clinical scenario for which multiple agents have been used (Table 2) . If the patient was sensitized pre transplant, various immunomodulatory therapies are often considered pre transplant and perioperatively [75•] . If the FCXM is positive, perioperative and early post-operative therapies are typically given (such as induction therapy and other adjunctive therapies). If antibodies persist post transplant or develop de novo, therapy is tailored to the individual and clinical presentation. Table 2 summarizes the various specific therapies that have been used to manage antibodies pre or post transplant and to treat AMR. Rituximab is a chimeric monoclonal antibody (mAB) against CD20 expressed on B cells that destroys cells via antibody-mediated cytotoxicity and complement fixation and activation. Basiliximab is a chimeric mAB against CD25 of the interleukin-2 (IL-2) receptor on T cells. By competing with IL-2 binding, T cell replication and activation of B cells is inhibited. Cyclophosphamide is an alkylating agent in the nitrogen mustard family that interferes with DNA duplication and RNA transcription. Alemtuzumab is a humanized rabbit mAB targeted at CD52 Antigen (Ag), a human leukocyte differentiation Ag on the surface of most blood lymphocytes, macrophages, and monocytes. It kills cell antibody-mediated cytotoxicity and complement fixation and activation. Bortezomib is a selective 26S proteasome inhibitor, which results in apoptosis of plasma cells. Carfilzomib is a secondgeneration, irreversible 20S proteasome inhibitor that is an alternative to bortezomib with an improved side-effect profile. Photophoresis involves treatment of a patient's leukocyte-rich plasma with a photosensitizing agent and ultraviolet A radiation prior to reinfusion. Affected leukocytes die over a 2-week period and cause a T cell-mediated suppressor response of other T cells [17••, 76] . Eculizumab is a mAB against IgG2/4, which targets and inhibits the complement cascade's terminal portion.
If DSAs are present in the setting of clinical AMR, treatment is indicated for AMR and the antibodies can be used as a marker for treatment response. Resolution of or decrease in DSA after treatment of AMR typically correlates with clinical improvement. Broad goals of treatment for AMR are discontinuation of cell injury and support for heart failure. Circulating antibodies can be removed with plasmapheresis. Residual levels can be Green indicates that no treatment should be considered, yellow indicates that treatment could be considered based on clinical circumstances, and red indicates that treatment should be done regardless of clinical status. Adapted from Colvin et al. [17••] . Abbreviations: AMR antibodymediated rejection, DG dysfunction graft, DSA donor-specific antibody, pAMR ISHLT pathologic grade of AMR, XM crossmatch suppressed with intravenous immunoglobulin (IVIG). Both B and T cells can be treated with corticosteroids; disease-modifying anti-rheumatic drugs (DMARD), such as alemtuzumab; or lymphoid irradiation [17••] . A more targeted T cell therapy is photophoresis, and B cellspecific therapies include rituximab, cyclophosphamide, and splenectomy. Finally, modulation of complement activity can be achieved with eculizumab and IVIG. Additionally, individuals' maintenance immunosuppressive regimens can be adjusted such as transition of those on cyclosporine to tacrolimus as well as increased doses of mycophenolate mofetil and cyclosporine [77] .
Thresholds of treatment for subclinical or pre-clinical AMR are more difficult to define, given that pathologic AMR can represent a spectrum (of subclinical, preclinical, acute clinical, and chronic disease process) as previously described, from pAMR 0 to pAMR 4 [78] . Further organization of these groups by the presence or absence of graft dysfunction and DSA allows customization of treatment considerations (Fig. 1) [17••] . Though there are no absolute recommendations regarding treatment, pAMR 3 is usually always treated as outcomes associated with it are otherwise grim, regardless of the presence of DSA or graft dysfunction.
Conclusions
New and pre-formed HLA DSAs are associated with worse outcomes in transplant recipients. In addition, non-HLA antibodies should be considered as a cause of AMR if there is suspicion without evidence of HLA antibodies. The frequency of screening for AMR should be based on risk stratification for development of AMR. Yet, the presence of antibodies alone post transplant does not constitute a diagnosis of AMR, which is a histologic and immunopathologic diagnosis. Treatment of posttransplant antibodies should be made in conjunction with consideration of AMR grade and graft dysfunction.
Future directions will involve improved detection methods and further understanding of non-HLA antibodies and de novo antibodies in the post-transplant population. Additionally, aggressive efforts are currently underway to provide more therapeutic options, often modeled on treatments provided in abdominal transplant recipients, as we refine potential treatment algorithms. Potential new therapies for the cardiac transplant patient will likely include a C1 esterase inhibitor (C1-INH) and IdeS (a Streptococcus pyogenes proteolytic enzyme) that is currently being used in kidney transplant patients.
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